Mediantechn (ALMDT) - Total Liabilities

Latest as of December 2025: €71.02 Million EUR ≈ $83.03 Million USD

Based on the latest financial reports, Mediantechn (ALMDT) has total liabilities worth €71.02 Million EUR (≈ $83.03 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ALMDT strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Mediantechn - Total Liabilities Trend (2008–2025)

This chart illustrates how Mediantechn's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Mediantechn balance sheet assets.

Mediantechn Competitors by Total Liabilities

The table below lists competitors of Mediantechn ranked by their total liabilities.

Company Country Total Liabilities
Value Added Technology Co. Ltd
KQ:043150
Korea ₩170.42 Billion
Expensify Inc
NASDAQ:EXFY
USA $50.84 Million
Spandana Sphoorty Financial Limited
NSE:SPANDANA
India Rs34.52 Billion
Garuda Construction & Engineering
NSE:GARUDA
India Rs1.90 Billion
CJ Freshway Corporation
KQ:051500
Korea ₩1.16 Trillion
Singer Thailand Public Company Limited
BK:SINGER-R
Thailand ฿1.01 Billion
Exacompta Clairefontaine
PA:ALEXA
France €367.69 Million

Liability Composition Analysis (2008–2025)

This chart breaks down Mediantechn's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Mediantechn balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.67 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.02 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.98 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Mediantechn's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Mediantechn (2008–2025)

The table below shows the annual total liabilities of Mediantechn from 2008 to 2025.

Year Total Liabilities Change
2025-12-31 €71.02 Million
≈ $83.03 Million
+21.74%
2024-12-31 €58.34 Million
≈ $68.20 Million
+26.20%
2023-12-31 €46.23 Million
≈ $54.05 Million
+10.05%
2022-12-31 €42.01 Million
≈ $49.11 Million
-5.50%
2021-12-31 €44.45 Million
≈ $51.97 Million
+21.29%
2020-12-31 €36.65 Million
≈ $42.84 Million
+146.94%
2019-12-31 €14.84 Million
≈ $17.35 Million
+63.89%
2018-12-31 €9.05 Million
≈ $10.59 Million
-1.65%
2017-12-31 €9.21 Million
≈ $10.76 Million
+17.78%
2016-12-31 €7.82 Million
≈ $9.14 Million
+6.99%
2015-12-31 €7.31 Million
≈ $8.54 Million
+78.46%
2014-12-31 €4.09 Million
≈ $4.79 Million
+880.23%
2013-12-31 €417.66K
≈ $488.29K
-14.49%
2012-12-31 €488.41K
≈ $571.00K
-90.97%
2011-12-31 €5.41 Million
≈ $6.33 Million
-26.18%
2010-12-31 €7.33 Million
≈ $8.57 Million
+70.29%
2009-12-31 €4.30 Million
≈ $5.03 Million
+194.86%
2008-12-31 €1.46 Million
≈ $1.71 Million
--

About Mediantechn

PA:ALMDT France Medical Devices
Market Cap
$176.64 Million
€151.09 Million EUR
Market Cap Rank
#17127 Global
#248 in France
Share Price
€3.97
Change (1 day)
-3.17%
52-Week Range
€2.68 - €6.59
All Time High
€17.80
About

Median Technologies SA engages in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development with operations spanning in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iSee for imaging services in clinical trials; eyonis for non-invasive diagnos… Read more